

It is illegal to post this copyrighted PDF on any website. Cognitive Behavioral Therapy for Olfactory Reference Syndrome:

A Case Report

Jasper B. Zantvoord, MD^{a,b,*}; Nienke Vulink, MD, PhD^a; and Damiaan Denys, MD, PhD^{a,c}

lfactory reference syndrome (ORS) is a psychiatric condition characterized by concerns about perceived body odor, which may be accompanied by repetitive behaviors to mask body odor and avoidance of social situations. ORS has been proposed as an obsessive-compulsive and related disorder in the *DSM-5*. There is no established standard treatment for ORS. Some case studies have reported (partial) response with clomipramine, 1,3,4 while others have reported nonresponse. The interpretation of previous case reports on behavioral therapy and eye movement desensitization and reprocessing (EMDR) is impeded by the paucity of objective outcome assessments. The properties of the properties of the partial of the processing (EMDR) is impeded by the paucity of objective outcome assessments. The properties of the process of the properties of the process of the proc

Case report. Ms A, a 23-year-old Creole woman with no history of physical disease, had been suffering from ORS symptoms for 10 years. She was diagnosed (DSM-IV criteria) with generalized anxiety disorder (GAD), which developed after the onset of ORS symptoms. She had an overvalued idea that she emitted a sweaty body odor that disgusted people around her. She interpreted other people's frowning or distancing themselves as proof for her beliefs. She experienced severe distress in confined spaces (classroom and public transport) where people could smell her presumed odor. She regularly checked her odor, showered every time she left home, and used excessive amounts of deodorant. She repeatedly sought consultation with dermatologists. Due to avoidance and distress, her study performance and social life were impaired. She had received supportive psychotherapy, which was associated with limited improvement. Ms A was therefore referred for assessment and further treatment.

Pretreatment physical, neurologic, and laboratory evaluation showed no abnormalities. Her pretreatment score on the Body Dysmorphic Disorder Modification of the Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS)¹⁰ was 28 out of 48, indicating moderate symptoms (Table 1). CBT

^aDepartment of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands

J Clin Psychiatry 2016;77(9):e1144–e1145 dx.doi.org/10.4088/JCP.15cr10451 was carried out with 8 fellow group members who were all suffering from body dysmorphic disorder (BDD). Treatment consisted of twice-weekly sessions with a total duration of 16 weeks. CBT was based on a previously published manual,¹³ which was adapted to facilitate group-based treatment. The first session entailed psychoeducation and establishment of treatment goals. In the second session, an exposure hierarchy was composed. During and between sessions, gradual and repetitive in vivo exposure with task concentration and response prevention were performed. The treatment manual was adapted specifically for Ms A to include tailored exposure exercises to evoke fear-inducing stimuli related to her emitting an offensive body odor. Examples included approaching someone on the street for small talk and, subsequently, standing close and talking to someone in a confined space and then doing so without using deodorant or showering beforehand. Cognitive restructuring was introduced to identify and adjust dysfunctional beliefs. In the final sessions, relapse prevention strategies were discussed. Apart from body-oriented therapy elements, such as progressive muscle relaxation (Jacobson technique) and breathing exercises, no concurrent treatments were performed.

Following treatment, Ms A's ORS symptoms fully remitted. For residual GAD symptoms, paroxetine 20 mg/d was initiated after CBT termination. Two months thereafter, GAD symptoms remitted (Table 1). In the following months, ORS and GAD symptoms remained in remission. Ms A resumed her studies and group fitness classes.

The present case is the first report of successful treatment of ORS combining cognitive and behavioral techniques. ORS and comorbid symptoms were assessed using objective rating scales, elaborating on previous reports on behavioral therapy and EMDR in ORS. 5,7-9 After CBT group treatment, ORS symptoms fully remitted and improvement was maintained for 6 months. Paroxetine treatment initiated after CBT could have contributed to maintenance of remission. Our findings are promising, because a standard treatment for ORS has not been established.^{2,6} The classification of ORS as an obsessive-compulsive spectrum disorder is a point of ongoing debate.² The group CBT in which our patient enrolled was designed for treatment of BDD. Nevertheless, ORS remitted, which gives some support for the classification of ORS as an obsessive-compulsive spectrum disorder. However, our observations should be interpreted with caution, as the effects noted could be based on nonspecific therapeutic factors and were limited to a single case. Therefore, further research, particularly a randomized controlled trial of the efficacy of CBT in ORS, is warranted.

^bThe Bascule Academic Centre for Child and Adolescent Psychiatry, Amsterdam. The Netherlands

^cNetherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands.

^{*}Corresponding author: Jasper B. Zantvoord, MD, Department of Psychiatry, Academic Medical Centre, Meibergdreef 5, Room PA2-226, 1105 AZ, Amsterdam, The Netherlands (j.b.zantvoord@amc.uva.nl).

 $^{@\} Copyright\ 2016\ Physicians\ Postgraduate\ Press,\ Inc.$

It is illegal to post this copyrighted PDF on any website.

Table 1. Olfactory Reference and Anxiety Symptom Severity Ratings Before and After CBT and at 6-Month Follow-up

			Follow-up 6 Months After CBT
	Before	After 16	(paroxetine 20 mg/d
Measure	CBT	Weeks of CBT ^a	used during this time)
Body Dysmorphic Disorder Modification of the	28	3	4
Yale-Brown Obsessive Compulsive Scaleb			
Dutch Dimensional Obsessive-Compulsive Scale ^c	23	2	3
Hamilton Anxiety Rating Scaled	41	25	8
Global Assessment of Functioning score	41–50	e	71–80

^aCBT was started in November 2014.

Abbreviation: CBT = cognitive-behavioral therapy.

Submitted: October 12, 2015; accepted December 21, 2015.

Online first: July 19, 2016.

Drug names: clomipramine (Anafranil and others), paroxetine (Paxil, Pexeva, and others).

Potential conflicts of interest: None.

Funding/support: None.

REFERENCES

- Lochner C, Stein DJ. Olfactory reference syndrome: diagnostic criteria and differential diagnosis. J Postgrad Med. 2003;49(4):328–331.
- Feusner JD, Phillips KA, Stein DJ. Olfactory reference syndrome: issues for DSM-V. Depress Anxiety. 2010;27(6):592–599.
- Dominguez RA, Puig A. Olfactory reference syndrome responds to clomipramine but not fluoxetine: a case report. J Clin Psychiatry. 1997;58(11):497–498.
- 4. Stein DJ, Le Roux L, Bouwer C, et al. Is olfactory reference syndrome an obsessive-compulsive spectrum disorder? two cases and a discussion. *J Neuropsychiatry Clin Neurosci*. 1998;10(1):96–99.
- McGoldrick T, Begum M, Brown KW. EMDR and Olfactory Reference Syndrome. J EMDR Pract Res. 2008;2(1):63–68.
- Lochner C, Stein DJ. Prevalence of olfactory reference syndrome in obsessive-compulsive disorder and social anxiety disorder. J Clin

- Psychiatry. 2014;75(11):1266.
- Beary MD, Cobb JP. Solitary psychosis—three cases of monosymptomatic delusion of alimentary stench treated with behavioural psychotherapy. Br J Psychiatry. 1981;138(1):64–66.
- 8. Gomez-Perez JC, Marks IM, Gutierrez-Fisac JL. Dysmorphophobia: clinical features and outcome with behavior therapy. *Eur Psychiatry*. 1994;9(5):229–235.
- Marks I, Mishan J. Dysmorphophobic avoidance with disturbed bodily perception: a pilot study of exposure therapy. Br J Psychiatry. 1988;152(5):674–678.
- Phillips KA, Hollander E, Rasmussen SA, et al. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. *Psychopharmacol Bull.* 1997;33(1):17–22.
- Domen AC, Borsboom D, Vullink NC. Psychometric Properties of the Dutch Dimensional Obsessive Compulsive Scale [master's thesis]. http://dare.uva. nl/cgi/arno/show.cgi?fid=509444. Amsterdam, The Netherlands: University of Amsterdam; 2013.
- Maier W, Buller R, Philipp M, et al. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988;14(1):61–68.
- Wilhelm S, Phillips KA, Fama JM, et al. Modular cognitive-behavioral therapy for body dysmorphic disorder. *Behav Ther*. 2011;42(4): 624–633.

^bA 12-item semistructured clinician-rated instrument designed to rate the severity of body dysmorphic disorder–related symptoms; has a range of possible scores of 0–48.

^cA 9-item semistructured clinician-rated instrument designed to rate the severity of obsessive-compulsive disorder–related symptoms; has a range of possible scores of 0–50.¹¹

^dA 14-item semistructured clinician-rated instrument designed to rate the severity of anxiety symptoms; has a range of possible scores of 0–56.¹²

^eNot measured at this time point.